The epidemiology of hepatitis C among injecting drug users in Belgium.
In industrialised countries, injecting drug use is currently the most important risk factor for infection with hepatitis C, resulting in high prevalence rates of hepatitis C among injecting drug users. To contain the hepatitis C epidemic major efforts should be done to prevent new infection among injecting drug users. Monitoring infection rates are crucial as it may provide feedback on the effectiveness of interventions. In this article the epidemiology of hepatitis C among injecting drug users in Belgium is briefly reviewed. More specifically the prevalence of anti-HCV antibodies, the prevalence of co-infections, the proportion of chronic HCV carriers, the distribution of genotypes and preventive measures among injecting drug users in Belgium are discussed and compared to the situation elsewhere in Western Europe.
Matheï
C
C
Department of General Practice, Katholieke Universiteit Leuven, Leuven, Belgium. catharina.mathei@pandora.be
Robaeys
G
G
Van Ranst
M
M
Van Damme
P
P
Buntinx
F
F
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D001530:Belgium / Q000453:epidemiology; D015897:Comorbidity; D005260:Female; D019698:Hepatitis C, Chronic / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D015819:Substance Abuse, Intravenous / Q000453:epidemiology* / Q000517:prevention & control; D016019:Survival Analysis